Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „RoActemra · 4.8 · RA patients“
Suchtreffer
Begriffe & Kennungen
RoActemra · 4.8 · Immunogenicity A total of 2876 patients have been tested for anti-tocilizumab antibodies in the 6-month contro
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In SC-I, a total of 625 patients treated with tocilizumab 162 mg weekly were tested for anti- t
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In SC-I, a total of 625 patients treated with tocilizumab 162 mg weekly were tested for anti- t
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the subcutaneous trial (WA28118), 46 of the 51 (90.2 %) patients tested for anti-tocilizumab
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the subcutaneous trial (WA28118), 46 of the 51 (90.2 %) patients tested for anti-tocilizumab
Eintrag öffnenRoActemra · 4.8 · In SC-II, a total of 434 patients treated with tocilizumab 162 mg every other week were tested for anti- tocil
Eintrag öffnenRoActemra · 4.8 · In SC-II, a total of 434 patients treated with tocilizumab 162 mg every other week were tested for anti- tocil
Eintrag öffnenRoActemra · 4.8 · In general, the adverse reactions in sJIA patients were similar in type to those seen in RA patients. The freq
Eintrag öffnenRoActemra · 4.8 · In the 12 week controlled phase, 16 % of patients in the tocilizumab group and 5.4 % of patients in the placeb
Eintrag öffnenRoActemra · 4.8 · In the open label extension phase (Trial WA18221), 13.2 % and 27.7 % of patients experienced a post- baseline
Eintrag öffnenRoActemra · 4.8 · In the open label extension phase, elevation in ALT or AST ≥ 3 × ULN occurred in 12 % and 4 % of patients, res
Eintrag öffnenRoActemra · 4.8 · Infections In the subcutaneous tocilizumab trial, the rate of infection in pJIA patients treated with subcutan
Eintrag öffnenRoActemra · 4.8 · Infections In the subcutaneous tocilizumab trial, the rate of infection in pJIA patients treated with subcutan
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infection in sJIA patients treated with subcutaneous tocilizumab was comparable to sJIA
Eintrag öffnenRoActemra · 4.8 · Infections The rate of infection in sJIA patients treated with subcutaneous tocilizumab was comparable to sJIA
Eintrag öffnenRoActemra · 4.8 · Infusion-related reactions In pJIA patients, infusion-related reactions are defined as all events occurring du
Eintrag öffnenRoActemra · 4.8 · Injection Site Reactions (ISRs) In the subcutaneous trial (WA28118), a total of 41.2 % (21/51) sJIA patients e
Eintrag öffnenRoActemra · 4.8 · Injection Site Reactions (ISRs) In the subcutaneous trial (WA28118), a total of 41.2 % (21/51) sJIA patients e
Eintrag öffnenRoActemra · 4.8 · Injection site reactions A total of 28.8 % (15/52) pJIA patients experienced ISRs to tocilizumab subcutaneous.
Eintrag öffnenRoActemra · 4.8 · Injection site reactions In the tocilizumab subcutaneous weekly group, a total of 6 % (6/100) patients reporte
Eintrag öffnen